#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cystic fibrosis lung B-cell small lymphocytic lymphoma recurrent Heavy menstrual bleeding Oesophageal achalasia Arteriovenous malformation Extra-osseous Ewing's sarcoma Cardiac failure acute Anal squamous cell carcinoma Glomerulonephritis Spinal muscular atrophy Fibrodysplasia ossificans progressiva Malignant fibrous histiocytoma Solitary fibrous tumour Juvenile idiopathic arthritis Adult T-cell lymphoma/leukaemia refractory More trials…

    Learn about Rare Diseases

    Prolymphocytic leukaemia Angiosarcoma non-metastatic Lymphangioma – Life with Disease Focal segmental glomerulosclerosis – Trials in Disease Factor IX deficiency – Life with Disease Congenital hypotransferrinaemia – Basic Information Pleural mesothelioma malignant – Treatment Toxic epidermal necrolysis – Life with Disease Brain stem glioma Ehlers-Danlos syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rezpegaldesleukin ALLERGEN EXTRACTS LUNSEKIMIG Progesterone, Micronised Epcoritamab Repagermanium Esketamine Hydrochloride Quercus Ilex Allergen Extract Dostarlimab Stiripentol Ponsegromab Ferric Derisomaltose Bp1.7881A Hydroxypropyl Cellulose Lf Methyl Aminolevulinate Nizatidine Sacituzumab Govitecan ULIXERTINIB Azd5004 Apixaban More therapies…

    Learn about Your Condition

    Renal disorder Pulmonary venous thrombosis Aneurysm ruptured Anaplastic thyroid cancer Infertility male Pneumothorax Vascular dementia Basal cell carcinoma Lichen sclerosus Mantle cell lymphoma stage II Pelvic venous thrombosis Liposarcoma recurrent Alveolar proteinosis Malignant melanoma stage IV Pancreatic carcinoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Mumdla Zqdkescc Kvhgx 2ub Djnfijiro 4dvii Hcvswib

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

    Recruiting

    3 1 1
    Investigated Drugs:
    • Imatinib Mesilate
    • [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE
    Finland France Germany Greece Hungary Italy +7
  • Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

    Recruiting

    2 1 1
    Investigated Drugs:
    • Human Normal Immunoglobulin (Iv)
    • Tocilizumab
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    France Greece Hungary Portugal Spain Sweden
  • Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

    Recruiting

    3 1 1
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Latvia Lithuania Poland Slovakia +1
  • Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

    Recruiting

    2 1
    Investigated Diseases:
    • Idiopathic pulmonary fibrosis
    Bulgaria Denmark France Germany Greece Hungary +4
  • A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

    Recruiting

    3 1 1
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Czechia Denmark Germany Greece Hungary Poland +1
  • Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

    Recruiting

    4 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • LUNSEKIMIG
    Belgium Denmark Estonia Finland France Germany +7
  • Efficacy and Safety of Inhaled Glycopyrronium Bromide Added to Budesonide and Formoterol Fumarate in Children 4‑12 Years with Asthma (Placebo‑Controlled)

    Recruiting

    2 1
    Investigated Drugs:
    • Formoterol Fumarate
    • Budesonide
    • Glycopyrronium Bromide
    Czechia Hungary Poland
  • Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastric cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Azd0901
    • Zolbetuximab
    • Capecitabine
    Belgium France Germany Hungary Italy The Netherlands +2
  • Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Emicizumab
    • Ro7589655
    Austria Belgium Denmark France Germany Hungary +5
  • Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

    Recruiting

    3 1 1
    Investigated Drugs:
    • Indacaterol Acetate
    • Mometasone Furoate
    • Salmeterol
    France Germany Hungary Poland Romania Slovakia +1
1 2 3 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!